Vantictumab

Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2][3].

Product Specifications

CAS Number

[1345009-45-1]

Product Name Alternative

OMP-18R5

UNSPSC

12352203

Target

Wnt

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vantictumab.html

Purity

99.40

Solubility

10 mM in DMSO|H2O

Smiles

[Vantictumab]

Molecular Weight

(143.16 kDa)

References & Citations

[1]Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38 (3) :821-830.|[2]Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184 (1) :53-62.|[3]Smith D C, et al. Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors[J]. Molecular Cancer Therapeutics, 2013, 12 (11_Supplement) : B24-B24.